Sagimet Biosciences Future Growth

Future criteria checks 0/6

Sagimet Biosciences's earnings are forecast to decline at 31.5% per annum while its annual revenue is expected to grow at 88% per year. EPS is expected to decline by 24% per annum.

Key information

-31.5%

Earnings growth rate

-24.0%

EPS growth rate

Biotechs earnings growth34.9%
Revenue growth rate88.0%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:0O2 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-183N/AN/A4
12/31/2025N/A-119N/AN/A5
12/31/2024N/A-48N/A-585
6/30/20242-29-23-23N/A
3/31/20242-28-23-23N/A
12/31/20232-28-24-24N/A
9/30/20232-27-24-24N/A
6/30/2023N/A-28-26-26N/A
3/31/2023N/A-28-27-27N/A
12/31/2022N/A-30-24-24N/A
12/31/2021N/A-24-22-22N/A
12/31/2020N/A-11-10-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0O2 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0O2 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0O2 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0O2 is forecast to have no revenue next year.

High Growth Revenue: 0O2 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0O2's Return on Equity is forecast to be high in 3 years time


Discover growth companies